
1. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1414-8. doi: 10.1016/j.bmcl.2011.01.021.
Epub 2011 Jan 11.

Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4)
HIV-1 replication.

Skerlj R(1), Bridger G, McEachern E, Harwig C, Smith C, Kaller A, Veale D, Yee H,
Skupinska K, Wauthy R, Wang L, Baird I, Zhu Y, Burrage K, Yang W, Sartori M,
Huskens D, De Clercq E, Schols D.

Author information: 
(1)Genzyme Corp., Waltham, MA 02451, USA. renato.skerlj@genzyme.com

A novel series of CXCR4 antagonists were identified based on the substantial
redesign of AMD070. These compounds possessed potent anti-HIV-1 activity and
showed excellent pharmacokinetics in rat and dog.

Copyright Â© 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.bmcl.2011.01.021 
PMID: 21295470  [Indexed for MEDLINE]

